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Abstract
Objective: De novo lipogenesis is involved in fatty acid biosynthesis and could be involved in the regulation of the
triglyceride storage capacity of adipose tissue. However, the association between lipogenic and lipolytic genes and the
evolution of morbidly obese subjects after bariatric surgery remains unknown. In this prospective study we analyze the
association between the improvement in the morbidly obese patients as a result of bariatric surgery and the basal
expression of lipogenic and lipolytic genes.
Methods: We study 23 non diabetic morbidly obese patients who were studied before and 7 months after bariatric surgery.
Also, we analyze the relative basal mRNA expression levels of lipogenic and lipolytic genes in epiploic visceral adipose tissue
(VAT) and abdominal subcutaneous adipose tissue (SAT).
Results: When the basal acetyl-CoA carboxylase 1 (ACC1), acetyl-CoA synthetase 2 (ACSS2) and ATP citrate lyase (ACL)
expression in SAT was below percentile-50, there was a greater decrease in weight (P=0.006, P=0.034, P=0.026), body
mass index (P=0.008, P=0.033, P=0.034) and hip circumference (P=0.033, P=0.021, P=0.083) after bariatric surgery. In
VAT, when the basal ACSS2 expression was below percentile-50, there was a greater decrease in hip circumference
(P=0.006). After adjusting for confounding variables in logistic regression models, only the morbidly obese patients with
SAT or VAT ACSS2 expression$P50 before bariatric surgery had a lower percentage hip circumference loss (,P50) after
bariatric surgery (SAT: P=0.039; VAT: P=0.033).
Conclusions: A lower basal ACSS2, ACC1 and ACL expression, genes involved in de novo lipogenesis, is associated with a
better evolution of anthropometric variables after bariatric surgery. Thus, the previous state of the pathways involved in
fatty acid metabolism may have repercussions on the improvement of these patients.
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Introduction
Alterations in lipogenesis and lipolysis, mechanisms involved in
the regulation of triglyceride storage, seem to be associated with
obesity [1]. The lipogenesis pathway can be influenced by the
supply of fatty acids-coenzyme A or glycerol phosphate, or by the
activity of enzymes at later stages of triglyceride synthesis. Glycerol
phosphorylation by glycerol kinase (GyK) and gluconeogenesis
(GNG) are involved in the availability of glycerol phosphate. A
regulatory step of GNG is the conversion of oxaloacetate to
phosphoenolpyruvate, catalyzed by phosphoenolpyruvate carbox-
ykinase (PEPCK). However, the role of GyK and PEPCK seems to
be limited in adipose tissue and is not well known in human
obesity [2]. Dysregulation of PEPCK might influence lipid
deposition and therefore contribute to obesity and diabetes [3,4].
In vivo studies have suggested that one possible site for
regulation of fatty acid synthesis from acetate is at the level of
the enzyme acetyl-CoA synthetase (ACSS) [5]. Mammals have two
types of ACSS: mitochondrial ACSS1 and cytosolic ACSS2 [6].
ACSS1 is a mitochondrial enzyme that produces acetyl-CoA for
oxidation in the tricarboxylic acid cycle [6]. Mitochondrial acetyl-
CoA produced by ACSS1 becomes citrate, which is then
preferentially exported to the cytosol and cleaved into acetyl-
CoA and oxaloacetate by ATP citrate lyase (ACL) [7]. This acetyl-
CoA can be used for lipid synthesis [8]. ACL is a critical enzyme
that regulates the initial step in lipid biosynthesis and is considered
a key enzyme linking glucose metabolism to lipid synthesis. ACSS2
is a cytosolic enzyme that catalyzes the formation of acetyl-
coenzyme A from coenzyme A and acetate [5,9], an essential
molecule utilized in various metabolic pathways including fatty
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31280acid [5,6,8,9]. Steiner et [10] suggested the role of this enzyme in
the control of fatty acid synthesis based on studies in brown
adipose tissue homogenates. In addition, acetyl-CoA carboxylase 1
(ACC1) mediates the conversion from acetyl-CoA to malonyl-
CoA. This molecule produced by ACC1 is thought to be used
selectively as a substrate for de novo lipogenesis [11]. Although de
novo lipogenesis can account for only a small fraction of total
triglyceride flux in adipose tissues, under certain conditions, such
as low fat ingest, may have some relevance. Its importance in the
determination of adipose tissue mass has not been resolved [12].
Changes in lipolysis might also shift the balance of fatty acid flux
and modulate fat mass. A modest energetic imbalance over time
can predispose to obesity. Conversely, fat loss by dieting is a slow
process and the involvement of the lipogenic and lipolytic enzymes
is not fully understood.
Bariatric surgery is almost the only effective strategy for treating
morbidly obese patients. However, morbidly obese patients do not
all lose the same weight after the same type of bariatric surgery,
nor do their accompanying disorders improve the same or at the
same rates. This variation between patients in metabolic progress
may depend on the metabolic state of their adipose tissue before
surgery, thus conditioning their metabolic response to the
operation. After bariatric surgery weight loss is mostly produced
by a reduction in the amount of stored fat. When lipid absorption
is limited (i.e. starvation or biliopancreatic diversion (BDP)), fatty
acids and glycerol come from lipolysis of adipose tissue and other
tissue reserves. The previous state of the different pathways
involved in fatty acid metabolism may have repercussions on the
improvement of these patients.
Recently, our group has shown an upregulation of genes
facilitating triglyceride/fatty acid cycling and a reduction in the
genes involved in de novo synthesis of fatty acids in morbid obesity
[1]. However, the association between lipogenic and lipolytic genes
and the evolution of morbidly obese subjects after bariatric surgery
remains unknown. In the present prospective study we analyzed the
association between the anthropometric and biochemical changes
produced in morbidly obese patients in the opposite situation, i.e.,
an improvement in these variables as a result of bariatric surgery,
with the basal expression of lipogenic and lipolytic genes.
Results
Bariatric surgery improved the anthropometric and
biochemical characteristics
Table 1 summarizes the characteristics of the morbidly obese
patients before and 7 months after their bariatric surgery. Seven
months after surgery, the anthropometric and biochemical
variables studied improved significantly. Waist and hip circum-
ferences, weight, BMI and HOMA-IR all decreased (18.268.8%,
17.666.7%, 26.7610.5%, 26.7610.5% and 65.3620.6%, re-
spectively) (p,0.001).
A lower basal mRNA expression of de novo lipogenesis
genes is associated with a better evolution of
anthropometric variables after bariatric surgery
The basal expression of ACSS2 (Figure 1) and ACC1 (Figure 2)
in VAT and SAT correlated negatively with the percentage
decrease in weight, BMI and hip circumference after bariatric
surgery (Table 2). The basal expression of PEPCK1 in SAT
correlated negatively with the percentage reduction in weight,
BMI and hip circumference (Table 2). The percentage reduction
in FFA correlated significantly with the basal expression of ACC1
and ACSS2 in SAT (Table 2). The percentage reduction in
HOMA-IR only correlated significantly with the basal expression
of PEPCK1 and ACL in SAT (Table 2). The expression of the
other genes studied in SAT and VAT (PPARc, DGAT1, AQP7,
GyK, ATGL, HSL and perilipin) did not correlate significantly
with the change in the biochemical variables studied after bariatric
surgery (data not shown).
Table 1. Anthropometric and biochemical variables in the morbidly obese patients before and after surgery.
Morbidly obese before surgery Morbidly obese after surgery
N (men/women) 23(9/14) -
Age (years) 39.8610.3 -
Weight (kg) 158.0628.3 114.4618.68
c
BMI (kg/m
2) 57.467.1 41.7066.59
c
Waist (cm) 146.1623.5 118.5615.09
c
Hip (cm) 160.3616.7 132.2612.69
c
Glucose (mM) 5.6761.01 4.7060.51
b
Cholesterol (mM) 4.9960.76 3.3960.60
c
HDL cholesterol (mM) 1.1560.38 0.9860.23
a
LDL cholesterol (mM) 3.0660.85 1.8760.047
c
VLDL cholesterol (mM) 0.6560.43 0.5460.20
Triglycerides (mM) 1.4560.88 1.2160.43
Free fatty acids (mM) 0.61460.287 0.47560.168
a
Insulin (pM) 31.5618.7 10.7464.51
c
HOMA-IR 8.1365.90 2.2161.02
c
BMI: body mass index; LDL: low density lipoprotein; VLDL: very low density lipoprotein; HOMA-IR: homeostasis model assessment of insulin resistance index. The results
are given as the mean 6 SD.
aP,0.05;
bP,0.01;
cP,0.001.
doi:10.1371/journal.pone.0031280.t001
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ACC1, ACSS2, ACL and PEPCK1 and the improvement of the
different anthropometric variables after bariatric surgery, the
patients were classified according to the 50
th percentile (,P50 or
$P50) of the distribution of the basal expression of each of these
three genes, both in SAT (Table 3) and in VAT. The association
between the expression of these genes and the improvement of the
different anthropometric variables was mainly seen in SAT. Table 3
shows the percentage reduction in weight, BMI, hip circumference,
FFA and HOMA-IR according to the expression of these genes in
SAT. We see that when the expression of ACC1, ACSS2 and ACL
was below P50, there was a greater percentage reduction in weight
(p=0.006, p=0.034, p=0.026, respectively), BMI (p=0.008,
p=0.0033, p=0.034, respectively), hip circumference (p=0.033,
p=0.021, p=0.083, respectively), levels of FFA (p=0.536,
p=0.019, p=0.161, respectively) and HOMA-IR (p=0.478,
p=0.606, p=0.002, respectively) after bariatric surgery (Table 3).
When the expression of PEPCK1 was below P50, there was a
greater percentage reduction in weight (p=0.049) after bariatric
surgery(Table3).Nosignificantdifferenceswerefoundforthe other
genes studied in SAT(PPARc, DGAT1,AQP7, GyK,ATGL, HSL
and perilipin) (data not shown).
In the VAT when the basal levels of ACSS2 expression were
below P50 the percentage reduction in hip circumference was
Figure 1. Association between the expression of acetyl-CoA synthetase 2 (ACSS2) and the percentage of reduction in the body
mass index (BMI) in subcutaneous (A) and visceral adipose tissue (B), and the hip circumference in SAT (C) and VAT (D). BMI: body
mass index.
doi:10.1371/journal.pone.0031280.g001
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differences were found in the percentage reduction in weight,
BMI, HOMA-IR or FFA (data not shown). For the other genes
studied in VAT (PPARc, ACC1, ACL, PEPCK1, DGAT1,
AQP7, GyK, ATGL, HSL and perilipin) no significant differences
were found in the percentage reduction in the hip circumference,
weight, BMI, HOMA-IR or FFA (data not shown).
The contribution of the ACC1, ACSS2, ACL and PEPCK1
gene expression to the improvement experienced after bariatric
surgery was calculated from a contingency table in which the
exposure variable was the level of gene expression above or below
the 50th percentile of the morbidly obese subjects before bariatric
surgery (,P50 or $P50) and the dependent variable was the
percentage reduction in the study variable (weight, BMI, waist and
hip circumferences, HOMA-IR or FFA) after the seven months of
follow-up (,P50 or $P50).
Morbidly obese patients with SAT ACC1 expression levels
below the 50th percentile (,P50) before bariatric surgery had a
relative risk (RR) of 4.375 (95% CI: 1.232–15.321) of having a
greater percentage weight loss ($P50) and a RR of 4.286 (95% CI:
1.196–15.325) of having a greater percentage hip circumference
loss ($P50) after bariatric surgery than those with SAT ACC1
Figure 2. Association between the expression of acetyl-CoA carboxylase 1 (ACC1) and the percentage of reduction in the body
mass index (BMI) in subcutaneous (A) and visceral adipose tissue (B), and the hip circumference in SAT (C) and VAT (D). BMI: body
mass index.
doi:10.1371/journal.pone.0031280.g002
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with ACC1 expression levels (data not shown).
Morbidly obese patients with SAT ACSS2 expression levels
$P50 before bariatric surgery had a higher risk (RR: 3.938, 95%
CI: 1.232–15.321) of having a lower percentage hip circumference
loss (,P50) after bariatric surgery than those with ACSS2
expression levels ,P50. Morbidly obese patients with VAT
ACSS2 expression levels ,P50 before bariatric surgery had a
higher risk (RR: 4.375, 95% CI: 1.232–15.531) of having a greater
percentage hip circumference loss ($P50) after bariatric surgery
than those with VAT ACSS2 expression levels $P50.
Morbidly obese patients with SAT ACL expression levels $P50
before bariatric surgery had a higher risk (RR: 2.852, 95% CI:
1.022–7.958) of having a lower percentage HOMA-IR loss
(,P50), a higher risk (RR: 2.406, 95% CI: 1.055–5.488) of
having a lower percentage weigh loss (,P50) and a higher risk
(RR: 2.917, 95% CI: 1.092–7.789) of having a lower percentage
BMI loss (,P50) after bariatric surgery than those with ACL
expression levels ,P50. In VAT, no significant results were found
with ACL expression levels (data not shown). With PEPCK1
expression levels, no significant results were found in SAT or VAT
(data not shown).
However, after adjusting for age, gender, weight and BMI in
logistic regression models, only the morbidly obese patients with
SAT or VAT ACSS2 expression levels$P50 before bariatric
surgery had a lower percentage hip circumference loss (,P50)
after bariatric surgery (SAT: P=0.039; VAT: P=0.033).
Given the relation between the expression of ACC1, ACCS2
and ACL and the anthropometric evolution of the morbidly
obese patients after their surgery, we analyzed the basal
anthropometric and biochemical variables according to the
basal expression of these enzymes (,P50 or $P50) in SAT and
VAT. We found no significant differences in any of the variables
between the two groups (ACC1,P50 versus ACC1$P50;
ACSS2,P50 versus ACSS2$P50; ACL,P50 versus ACL$
P50) (data not shown), with the exception of FFA. Those
morbidly obese patients with a basal expression of SAT
ACSS2,P50 had a higher basal FFA concentration than those
Table 2. Significant correlations (p) found between basal mRNA expression and the anthropometric and biochemical variables
studied.
% reduction
in weight
% reduction in hip
circumference
% reduction
in BMI
% reduction
in FFA
% reduction in
HOMA-IR
ACC1 SAT 20.732 (0.001) 20.624 (0.033) 20.731 (0.001) 20.459 (0.055) Ns
VAT 20.522 (0.023) 20.639 (0.010) 20.576 (0.014) Ns Ns
ACSS2 SAT 20.521 (0.039) 20.566 (0.018) 20.526 (0.052) 20.519 (0.027) Ns
VAT 20.623 (0.004) 20.619 (0.015) 20.710 (0.001) Ns Ns
ACL SAT Ns Ns Ns Ns 20.592 (0.006)
VAT Ns Ns Ns Ns Ns
PEPCK1 SAT 20.529 (0.034) 20.749 (0.002) 20.529 (0.049) Ns 20.492 (0.038)
VAT Ns Ns Ns Ns Ns
BMI: body mass index; FFA: free fatty acids; HOMA-IR: homeostasis model assessment of insulin resistance index; ACC1: acetyl-coenzyme carboxylase 1; ACSS2: acetyl-
CoA synthetase short-chain family member 2; ACL: ATP citrate lyase; PEPCK1: phosphoenolpyruvate carboxykinase 1; SAT: subcutaneous adipose tissue; VAT: visceral
adipose tissue; Ns: not significant. Correlation analyses were made with general linear models to adjust by age, gender, and baseline body weight and BMI as
independent covariate.
doi:10.1371/journal.pone.0031280.t002
Table 3. Reduction in the anthropometric and biochemical variables according to the 50
th-percentile of the expression of different
genes in subcutaneous adipose tissue.
% reduction
in weight
% reduction in hip
circumference
% reduction
in BMI
% reduction
in FFA
% reduction in
HOMA-IR
ACC1 ,P50 33.668.3
b 21.768.5
a 33.668.3
b 24.9638.7 71.8617.7
$P50 20.768.4 14.663.6 20.368.8 223.26118.1 59.5622.9
ACSS2 ,P50 31.568.5
a 20.967.8
a 31.568.5
a 37.7631.2
a 66.5620.3
$P50 20.269.6 13.762.6 19.5610.2 246.76121.7 63.0623.5
ACL ,P50 27.4610.8
a 19.6610.3 27.2611.3
a 7.1658.8 73.7612.7
b
$P50 20.764.0 18.065.3 20.764.0 242.5639.6 50.2616.6
PEPCK1 ,P50 30.666.5
a 19.165.6 30.666.5 24.6636.5 72.8618.1
$P50 22.3612.3 16.167.9 22.0613.1 227.76123.3 58.7622.2
BMI: body mass index; FFA: free fatty acids; HOMA-IR: homeostasis model assessment of insulin resistance index; ACC1: acetyl-coenzyme carboxylase 1; ACSS2: acetyl-
CoA synthetase short-chain family member 2; ACL: ATP citrate lyase; PEPCK1: phosphoenolpyruvate carboxykinase 1;
aP,0.05;
bP,0.01;
cP,0.001: significant differences between the percentage reduction in the different variables according to the 50
th percentile of the expression of each of the genes.
doi:10.1371/journal.pone.0031280.t003
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p=0.024).
Discussion
The mayor finding of this study is that de novo lipogenesis of
adipose tissue seem to be involved in the medium-term evolution
of anthropometric variables after bariatric surgery. To date, no
studies exist that show the relationship between adipose tissue gene
expression and weight loss after bariatric surgery. In this study we
see the association between baseline lipogenic and lipolytic genes
expression levels with change of anthropometric variables after
bariatric surgery. Previously, we have study the association
between basal expression level and basal anthropometric variables
[1]. Our results, like those of others [13,14], show that an-
thropometric and biochemical variables improve significantly in
morbidly obese patients after bariatric surgery. After BPD, weight
loss is primarily due to a selective malabsorption [15]. Neverthe-
less, anthropometric variables improve more in some patients than
others. Though various physiological factors and other mecha-
nisms are involved in this weight loss, they are not all fully
understood. The lipogenic capacity of adipose tissue could be a
variable to consider, as seen from this study. The lower basal
expression of the genes involved in de novo fatty acid synthesis was
associated with a better short-term anthropometric evolution in
these patients after bariatric surgery.
After bariatric surgery, predominantly lipolytic state, fatty acid
re-esterification acts as a retro-control pathway to reduce FFA
release. In the lipolytic state, GNG is the main provider of G3P,
and the key enzyme of GNG is PEPCK1 [2,16]. In previous
studies, adipose tissue GNG has been associated with obesity
[1,3,4]. The negative association found between PEPCK1 and
variables related to weight loss indicates that PEPCK1 could, to a
certain extent, be associated with the control of adipose tissue
triglyceride storage in morbidly obese patients. A lower GNG,
pathway that generates G3P to lipogenesis, would be directly
related with a greater weight loss.
Biliopancreatic diversion produces lipid malabsorption [15],
with reduced levels of plasma FFA and interruption of the Randle
cycle. In the biosynthesis of fatty acids, the regulation of the first
steps in de novo lipogenesis may be of great importance. ACC1 is
predominantly expressed in lipogenic tissues, such as adipose tissue
[17]. ACC1 mediates the initial step of the fatty acid synthesis,
suggesting that ACC1 could play a crucial role in the regulation of
lipogenesis. As other studies [17,18], our data support a potential
role for ACC1 in the development of obesity. The expression of
ACC1 is associated with variables related with weight loss.
Inactivation of ACC1 would result in inhibition of fatty acid and
malonyl-CoA synthesis, reduced lipid accumulation in adipose
tissue and stimulation of fatty acid oxidation [19].
Previous studies suggest that ACCS2 has an important role in
the control of fatty acid synthesis in adipose tissue [10]. The
present study shows that morbidly obese patients with a lower
expression of ACSS2 in SAT have higher plasma levels of FFA. It
is also in agreement with studies showing that a high fat diet [10],
fasting or addition of fatty acids in cultured cells [9] produce
inhibition of ACSS2 activity. In all these cases the fatty acids
increase. Our results also show that those morbidly obese persons
who have a lower basal expression of ACSS2 in SAT experience a
greater percentage reduction in plasma FFA after bariatric
surgery. This greater reduction may be the consequence of lower
synthesis of lipids from acetate, given the lower expression of
ACSS2. As we showed, this lower expression of ACSS2 would
result in a greater reduction in adipose tissue after bariatric
surgery. The current study clearly demonstrates that a lower basal
expression of the ACSS2 gene in VAT and SAT is associated with
a greater loss of weight, BMI and hip circumference after BPD.
ACL catalyzes the production of cytosolic acetyl-CoA and
oxaloacetate from citrate, thereby linking cellular glucose
catabolism and de novo lipid synthesis. As we showed, a lower
expression of ACL in SAT would result in a greater reduction of
insulin resistance, weight and BMI after bariatric surgery. As other
studies [20], our data support a potential role for ACL in the
development of obesity. However, contradictory studies exist on
the role of ACL in obesity [20–22]. Our results demonstrate that
ACL is associated with variables related with weight loss. This
enzyme could play a crucial role in the regulation of lipogenesis
and could be involved in the improvement of insulin resistance at
the whole-body level, as other authors suggest [23]. Although of
greater complexity in the regulation of cell lipid biosynthesis,
ACSS2, ACC1 and ACL are sites of control of the regulation in
the overall process of fatty acid synthesis. While the importance of
the role of fatty acids in the regulation of obesity is well known, our
findings go beyond this. We show the possible role of the
regulation of the first steps in de novo synthesis on the course of
anthropometric variables after bariatric surgery.
Previous results suggest differing degrees of involvement of VAT
and SAT in obesity and insulin resistance [1]. Our results also
suggest that the degree of involvement of VAT and SAT in the
evolution of anthropometric variables after bariatric surgery
differs. Since BPD causes malabsorption in small intestine, it is
possible that effects of this malabsorption could be enhanced in
VAT. However, basal SAT expression levels of genes involved in
de novo lipid synthesis show a higher involvement than VAT
expression levels in the changes produced in the anthropometric
variables as a result of bariatric surgery. For example, VAT ACL
and PEPCK gene expression is not associated with the changes
produced in the anthropometric variables. Recently has been
suggested that increasing weight loss attenuates the preferential
loss of VAT vs. SAT fat [24]. Also, changes in the foregut incretin
pattern, the reduction in free fatty acids, or other changes in the
gastrointestinal tract after BDP could differently affect to VAT and
SAT. These two adipose tissues are metabolically different and the
response to hormones differ [25,26]. These differences may partly
be explained by the regional variations in the response to the
action of insulin [25,27].
The results of this study suggest that inactivation of de novo
lipogenesis in adipose tissue, which would reflect good adaptation
of the adipose tissue to the excess of fat and FFA, may influence
the loss of adipose tissue after treatment. When the absorption of
fat decreases, as a consequence of bariatric surgery, adipose tissue
is obliged to increase lipolysis. Those morbidly obese patients
whose basal de novo lipogenesis is more inactivated are better suited
metabolically to experience a more drastic reduction in fat depots.
However, we were unable to measure the amount of fat lost nor
the sites where it was lost by more exact methods, such as
computerized tomography or magnetic resonance imaging. More
complete studies are now required to confirm the physiological
role of these enzymes in the regulation of cellular energy
metabolism. The benefits and risks of modulating a single
component of this complex system remain to be explored, with
vigilance for possible unpredicted effects at sites remote from
adipose tissues.
In conclusion, de novo lipogenesis seem to be involved in the
medium-term evolution of several anthropometric variables after
bariatric surgery. The basal status of the enzymes involved in de
novo lipogenesis may condition the response of morbidly obese
persons to this surgery. Different markers are required to help
De Novo Lipogenesis and Course of Morbid Obesity
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after bariatric surgery or other therapeutic interventions. Also,
These markers will enable more efficient selection of the type of
treatment in such a prevalent disease as obesity, as well as
identification of those patients who will respond better.
Materials and Methods
Subjects
The study included 23 non diabetic morbidly obese patients (BMI
57.465.2 Kg/m
2) who were studied before and 7 months after
bariatric surgery [28–30]. All the patients underwent open
biliopancreaticdiversion of Scopinaro (BPD).Patientswereexcluded
if they had type 2 diabetes mellitus, cardiovascular disease, arthritis,
acute inflammatory disease, infectious disease, or were receiving
drugs that could alter the lipid profile or the metabolic parameters at
the time of inclusion in the study. The weight of all the persons had
been stable for at least one month and none had renal involvement.
All participants gave written informed consent and the study was
reviewed and approved by the Ethics and Research Committee of
Virgen de la Victoria Clinical University Hospital, Malaga, Spain.
Laboratory measurements
Blood samples were collected after a 12-hour fast, before and 7
months after bariatric surgery [28–30]. The serum was separated
and immediately frozen at 280uC. Serum biochemical parameters
were measured in duplicate. Serum glucose, cholesterol, HDL
cholesterol, triglycerides (Randox Laboratories Ltd., Antrium,
UK) and free fatty acids (FFA) (WAKO Chemicals, Richmond,
VA) were measured by standard enzymatic methods. LDL and
VLDL cholesterol were calculated by Friedewald’s formula. The
insulin was analyzed by an immunoradiometric assay (BioSource
International, Camarillo, CA), showing a 0.3% cross-reaction with
proinsulin. The homeostasis model assessment of insulin resistance
index (HOMA-IR) was calculated from fasting insulin and glucose
with the following equation: HOMA-IR=fasting insulin (mIU/
mL)6fasting glucose (mol/L)/22.5. The percentage change in the
different anthropometric and biochemical variables as a conse-
quence of the bariatric surgery was calculated as: (basal
variable2variable at 7 months)6100/basal variable [31].
Visceral and subcutaneous adipose tissue mRNA
We analyzed the relative basal mRNA expression levels of
lipogenic and lipolytic genes in epiploic visceral adipose tissue
(VAT) and abdominalsubcutaneous adiposetissue (SAT).Five grams
of VAT and SAT were obtained during bariatric surgery in the
morbidly obese patients [1,32]. The biopsy samples were washed in
physiological saline and immediatelyfrozen in liquidnitrogen.Biopsy
samples were maintained at 280uC until analysis. Frozen adipose
tissue was homogenized with an Ultra-Turrax 8 (Ika, Staufen,
Germany). Total RNA was extracted using RNeasy lipid tissue midi
kit(QIAGENScience, Hilden, Germany), and total RNAwastreated
with 55URNasefree deoxyribonuclease (QIAGEN) following the
manufacturer’s instructions. The purity of the RNA was determined
by the absorbance260/absorbance280 ratio on the Nanodrop. The
integrity of total purified RNA was checked by denaturing agarosegel
electrophoresis and ethidium bromide staining. Total RNA was
reverse transcribed to cDNA by using a high-capacity cDNA reverse
transcription kit with RNase inhibitor (Applied Biosystems, Foster
City, CA). The cDNA was used for quantitative real-time PCR with
duplicates. We analyzed the relative basal mRNA expression levels of
peroxisome proliferator-activated receptor-a ˜( P P A R a ˜) (Hs00234592_
m1, RefSeq. NM_005037.5, NM_015869.4, NM_138711.3 and
NM_138712.3), acyl Coenzyme A:cholesterol acyltransferase
(DGAT1) (Hs00201385_m1, RefSeq. NM_012079.4), aquaporin 7
(AQP7) (Hs00357359_m1, RefSeq. NM_001170.1), acetyl-CoA
carboxylase 1 (ACC1) (Hs00167385_m1, RefSeq. NM_198834.1,
NM_198836.1, NM_198837.1, NM_198838.1 and NM_198839.1),
acetyl-CoA synthetase short-chain family member 2 (ACSS2)
(Hs00218766_m1, RefSeq. NM_001076552.2, NM_018677.3 and
NM_028046.1), ATP citrate lyase (ACL) (Hs00982738_m1, RefSeq.
NM_001096.2 and NM_198830.1), phosphoenolpyruvate carbox-
ykinase (PEPCK) (Hs00159918_m1, RefSeq. NM_002591.3), glyc-
erol kinase (GyK) (Hs02340011_g1, RefSeq. NM_000167.4 and
NM_203391.2), adipose triglyceride lipase (ATGL) (Hs00386101_
m1, RefSeq. NM_020376.3), hormone-sensitive lipase (HSL)
(Hs00193510_m1, RefSeq. NM_005357.2), and perilipin
(Hs00160173_m1, RefSeq. NM_001145311.1 and NM_002666.4).
We choose these genes because, previously, we have study the
association between these lipogenic and lipolitic genes with basal
anthropometric and biochemical variables [1]. The cycle threshold
(Ct) value for each sample was normalized with the expression of
PPIA (Hs99999904_m1). There is no variation in the expression of
this housekeeping gene in the condition tested. Real-time quantitative
PCR was performed on a 7900HT Fast real-time PCR system using
commercial Taqman assays (Applied Biosystems) [33]. SDS software
2.3 and RQ Manager 1.2 (Applied Biosystems) were used to analyze
the results with the comparative Ct method (22DDCt). All data were
expressed as an n-fold difference relative to the calibrator (a mixture
of the SAT and VAT tissues was used as calibrator sample).
Statistical analysis
The statistical analysis was done with SPSS (Version 11.5 for
Windows; SPSS, Chicago, IL). The Wilcoxon test for paired
samples was used to analyze the differences in the biological
variables between the first and the second sampling, 7 months after
the operation. General lineal models were calculated to estimate the
correlations between variables. The Mann-Whitney test was used to
compare the results of the two groups of morbidly obese patients,
defined according to whether the expression of the lipogenic
enzymes analyzed (ACSS2 and ACC1) was below the 50
th
percentile (,P50) or above it ($P50). We choose 50th percentile
to have two groups with similar number of patients in each group.
The contribution of the gene expression to the improvement seen
after bariatric surgery was calculated from a contingency table in
which the exposure variable was the level of gene expression above
or below the 50th percentile of the morbidly obese subjects before
bariatric surgery and the dependent variable was percentage
reduction in the study variable (weight, BMI, waist and hip
circumferences, HOMA-IR or FFA) over the seven months of
follow-up. Statistical significance was calculated from the x2 test.
Logistic regressions were used to determine the contribution of the
gene expression to the improvement seen after bariatric surgery,
after adjusting for age, gender, weight and BMI. Values were
considered to be statistically significant when the P#0.05. The
results are given as the mean 6 SD.
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